LAUSR

Trisomy 13, also known as Patau syndrome, is the third most common aneuploidy, occurring in approximately 1 in 5000–10,000 live births. This condition is associated with holoprosencephaly, profound developmental delay, and is considered to be a life-limiting condition with less than 10% survival ex utero. In addition to the neonatal implications, trisomy 13 is also associated with a well-documented 2–20-fold increased risk of hypertensive disorders of pregnancy with 25–40% of trisomy 13 pregnancies affected with a hypertensive disorders. Possible hypotheses to explain the increase in hypertensive disorders of pregnancy include an increase in soluble fms-like tyrosine kinase-1 (sFLt-1) in trisomy 13 placentas compared with control placentas. sFlT-1 is located on chromosome 13, and thus, women with a trisomy 13 fetus have more circulating sFlT-1. sFlt-1 acts by inhibiting the pro-angiogenic effects of vascular endothelial growth factor and placental growth factor on vascular endothelial cells. The sensitivity of cell-free DNA (cfDNA) screening for trisomy 13 is lower than for Down syndrome due to the GC content of chromosome 13. However, the specificity remains quite high. Because trisomy 13 is a rare aneuploidy, the positive predictive value following positive cfDNA result for trisomy 13 remains comparatively lower than for Down syndrome or trisomy 18. It is therefore common for a cfDNA result positive for trisomy 13 to be a false positive (i.e. diagnostic testing reveals a normal karyotype). Many of these false positives may be a result of confined placental mosaicism (CPM), though extensive cytogenetic analysis of the placenta after delivery is needed to confirm CPM. CPM is more common for trisomy 13 compared with other aneuploidies, and there is empiric evidence supporting the relevance to fetal cfDNA. After a high-risk cfDNA result for trisomy 21, 18, 13, and monosomy X, the likelihood of finding chorionic villus sampling mosaicism and the need for amniocentesis are, respectively, 2, 4, 22, and 59%. Given the increased risk of gestational hypertensive disorders with fetal trisomy 13, it is possible that women with false positive cfDNA result for trisomy 13 may be at increased risk of gestational hypertensive disorders as well because of CPM. We present a case series of six women with a cfDNA results screen positive for trisomy 13, who subsequently were found to have normal karyotypes or normal neonatal outcome. Four out of the five women (80%) for whom delivery information was available went on to develop gestational hypertensive disorders, one of which was severe and required preterm delivery. Further details regarding screening results, diagnostic testing results, and delivery details can be seen in Table 1. For the purposes of this series, the diagnosis of each gestational hypertensive disorder was made by the primary physician. However, these were also reviewed and validated by the study team using the International Society for the Study of Hypertension in Pregnancy guidelines. This study was approved by the Institutional Review Board at the University of North Carolina at Chapel Hill. Clearly, the distress a family faces in the setting of a positive screening test cannot be overlooked, especially in the setting of a life-limiting condition. Even after a normal amniocentesis and ultrasound, many families still feel a high degree of anxiety about their pregnancy. Many providers consider only the fetal risk in this setting, and thus, that risk appears resolved after diagnostic testing shows a normal karyotype. However, given the potential association with an increased risk for gestational hypertensive disorders, pregnancies should be monitored for signs and symptoms of gestational hypertensive disorders. Future prospective studies of maternal outcomes in the setting of false positive cfDNA results are needed to further understand the association between false positive cfDNA results, CPM, and hypertensive disorders of pregnancy.